Dendreon Announces Preliminary Analysis of its First Phase III Provenge Trial; Results Support New Approach in Fighting Prostate Cancer.
Business Wire › August 09, 2002
Linked as:
Extract
Dendreon Announces Preliminary Analysis of its First Phase III Provenge Trial; Results Support New Approach in Fighting Prostate Cancer.
Business Editors & Health/Medical Writers
BIOWIRE2K SEATTLE--(BW HealthWire)--Aug. 9, 2002 Dendreon Corporation (Nasdaq:DNDN) today announced preliminary results from its analysis of what it believes is the first randomized, double blind placebo controlled Phase III study of a cancer vaccine. The product, Provenge(TM) (APC 8015), is Dendreon's investigational vaccine for the treatment of hormone resistant prostate cancer. The investigational drug evaluates a new biologi...See the full content of this document
Sponsored links
